Upcoming Webinars
Friday, December 8, 2023
10:00AM EST | 3:00PM UTC | 4:00PM CET
Most Recent
Dec 2023
This webinar will provide a brief background on tokenization and its benefits. It will focus on end-to-end considerations for tokenizing data of clinical trial participants and designing fit for purpose studies based on linked real-world datasets. This webinar will outline (i) criteria for selecting clinical trials suitable for tokenization, (ii) highlight operational and evidence generation complexities and present potential options at various steps needed before, during, and after the clinical trial to enable tokenization, (iii) elucidate how to create and use linked datasets to derive fit for purpose real world evidence.
Nov 2023
The ISPOR HEOR Competencies Framework https://www.ispor.org/strategic-initiatives/more/heor-competencies-framework, originally published in 2020, provides a set of competencies to serve as a guide on the knowledge, attitudes, and behaviors needed to perform effectively in the HEOR discipline. As the HEOR field advances, so do the job types and the breadth of topics in which professionals must demonstrate competence. An update to the Competencies Framework is currently underway by an ISPOR workgroup to ensure its currency and comprehensiveness, especially with regards to diversity, equity, and inclusion; statistics and data science including Artificial Intelligence/Machine Learning; and other topics.
Oct 2023
The purpose of this webinar is to address this topic from the patients' perspective, outline how patients can be involved in the development and implementation of digital health initiatives and the impact and value for the patient community, including more ethical, faster, effective, and appropriate outcomes.
Oct 2023
The aim of this webinar is to discuss real-life examples on how biosimilar adoption has positively impacted care and patient access to biological therapies, focusing on testimonies from patient, policy, and healthcare professional representatives. Speakers are invited to converse on what the tangible benefits are that biosimilars have delivered for patients, and how biosimilar availability has supported access to care and the implementation of optimized disease management initiatives.
Oct 2023
This webinar will address when and why external control arms (ECA) are used, the acceptable types of data and methods to build ECAs, and circumstances under which ECAs are accepted from regulatory and HTA bodies.
Sponsored by Lane Clark & Peacock LLP
Oct 2023
In this webinar, we will give an overview of LLMs and share practical advice and cutting-edge examples about how to use them to help carry out real-world evidence (RWE) studies. We will also show how integrating GPT into population health analytics enables complex real-world datasets to be explored using simple language queries to transform the way that decision makers use data to identify unmet health needs.
Clinical Outcomes
Feb 2023
The workshop will use real-time polling to understand the audience’s experiences with data collection fraud online and the methods used to prevent and identify data collection fraud. We will encourage audience members to share their own strategies, learnings, and challenges.
Jan 2023
An ageing population means an urgent need for better and effective treatment for age-related illnesses. Despite billion-dollar investments for drug development for these conditions, especially neurogenerative diseases, there is a low success rate and it is a slow process.
Sponsored by Evidera, a PPD Company
Oct 2022
This webinar will explore what the SUCRA is, demonstrate how it can be meaningfully impacted by network composition (even in simple networks), and suggest corrections to common errors in the reporting of SUCRAs.
Sep 2022
Asia Pacific regional markets, including but not limited to mainland China, Japan, South Korea and Taiwan, play increasingly important roles in global clinical development. Patient-centric endpoints via clinical outcome assessments (COAs) and electronic COAs (eCOAs), are getting more and more attention in clinical research design and execution.
Economic Evaluation
Sponsored by FIFARMA
Aug 2023
Value-Based Procurement (VBP) is a critical element of a value-based healthcare system, offering a transformative purchase approach that addresses underlying barriers to access to innovative treatments. Unlike the traditional procurement methods that focus primarily on cost containment, VBP considers multiple factors, including the unique circumstances of each country, such as local disease burden, health priorities, infrastructure, supply chain, ability to pay for healthcare, and budget processes.
Jul 2023
This webinar aims to provide insights into the economic evaluation of digital health technology, which presents unique challenges compared to pharmaceuticals, healthcare services, and medical devices. In this webinar, you will learn about the current role of health economics and outcomes research in assessing the value of digital health technologies, as well as the impact of digital health interventions in today’s healthcare systems.
Apr 2023
In this forum, the OSM Special Interest Group has selected leaders in the field of health economics to describe their approach to OSMs. Mohsen Sadatsafavi will introduce the Peer Models Network and PRISM service as part of "Open-access modelling as a companion to open-source modelling” illustrated with an example implemented for Chronic Obstructive Pulmonary Disease (the Evaluation Platform in COPD (EPIC) model.)
Oct 2022
Many health systems in Africa are generally characterized by high burden of out-of-pocket payment by patients at the point of care and increased exposure of clients to catastrophic health payments. However, there are recent moves by many African countries to improve their health financing systems and institute health insurance in a bid to ensure universal health coverage.
Health Technology Assessment
Sep 2023
This webinar will provide an educational opportunity for the ISPOR membership to learn about how distributional cost-effectiveness analysis (DCEA) can be applied in the US setting. This webinar will introduce the method, discuss the current state of foundational data in the US and highlight a recent case study to illustrate data sources that can be leveraged in more routine DCEA application.
Jun 2023
This webinar is based off discussions that were held at the 2023 ISPOR HTA Roundtable – Asia Pacific on 8 March 2023. The HTA Roundtable focused on how countries or jurisdictions in the Asia Pacific region are assessing digital health technologies. This webinar will provide perspectives from different stakeholders and jurisdictions on the status of digital health assessments in the region.
Jun 2023
This webinar is aimed at all those who undertake research and development as well as value assessment of therapies and diagnostics in the rare disease space. It aims to expose the “diagnostic odyssey” and explain why a definitive diagnosis is not only important for patients but also for those assessing value. Objectives are to 1) explain what can be done to improve diagnosis in rare diseases and 2) why it matters in the context of value assessment.
Oct 2022
Many health systems in Africa are generally characterized by high burden of out-of-pocket payment by patients at the point of care and increased exposure of clients to catastrophic health payments. However, there are recent moves by many African countries to improve their health financing systems and institute health insurance in a bid to ensure universal health coverage.
Real-World Data & Information Systems
Dec 2023
This webinar will provide a brief background on tokenization and its benefits. It will focus on end-to-end considerations for tokenizing data of clinical trial participants and designing fit for purpose studies based on linked real-world datasets. This webinar will outline (i) criteria for selecting clinical trials suitable for tokenization, (ii) highlight operational and evidence generation complexities and present potential options at various steps needed before, during, and after the clinical trial to enable tokenization, (iii) elucidate how to create and use linked datasets to derive fit for purpose real world evidence.
Sep 2023
This webinar will cover the opportunities and challenges of collecting real-world data (RWD) and generating real-world evidence (RWE) for making better decisions in healthcare, specifically in Health Technology Assessment (HTA).
Jul 2023
In oncology, sequential use of treatments with different mechanisms of action is common practice to overcome cross-resistance . Over the past decade, treatment sequencing with novel immunotherapy and targeted agents has contributed to substantial improvement in clinical outcomes in cancer patients. However, such clinical practice introduces methodology challenges for HTA.
Sponsored by PINC AI™ Applied Sciences, a Division of Premier
Jun 2023
Join us as we discuss how the healthcare landscape is changing in technology and clinical trial innovation, including diversity improvement, leveraging real-world evidence, comparative arms, and decentralized clinical trials.
Patient-Centered Research
Sep 2023
Stated preference surveys often involve communicating large volumes of complex and/or unfamiliar medical information to provide context for respondents. This webinar examines innovative uses of technology to advance discrete choice experiment (DCE) research within health preference research. They will explore the different technologies that can be integrated into preference surveys illustrating how technology can better inform and potentially engage respondents.
Jul 2023
With the public comment period open until July 2023, this webinar will also present ISPOR members with the opportunity to ask questions and provide comments that will help inform ISPOR’s response on the draft guidance 4 document.
Sponsored by PINC AI™ Applied Sciences, a Division of Premier
Jun 2023
Join us as we discuss how the healthcare landscape is changing in technology and clinical trial innovation, including diversity improvement, leveraging real-world evidence, comparative arms, and decentralized clinical trials.
Mar 2023
In this webinar series, we will hear from patient representatives and FDA staff to learn what is covered in this guidance series and what these new guidances mean for patient-focused drug development and the HEOR community.
Medical Technologies
Sep 2023
The multi-stakeholder panel in this webinar will discuss how to strike the balance between openness and security in the process of health data collection for the successful value assessment regarding digital solutions.
Sponsored by Parexel
Feb 2023
Focusing on clinical neurosciences (CNS), and using first-hand experience from a Parkinson’s study, experts from Parexel discuss how to integrate eCOA science and sensor technology into clinical trials.
Sponsored by Replica Analytics
Sep 2022
This webinar presents a brief tutorial on synthetic data generation, an overview of its privacy preserving properties, and then review the results from studies evaluating the validity of analyses using synthetic data.
Sponsored by Merck & Co., known as MSD outside the United States and Canada
May 2022
Next-generation sequencing (NGS) is the key to precision medicine in oncology and delivers several benefits across the patient care pathway, from providing patients with a tailored therapeutic strategy, increasing efficiency in healthcare systems delivery of care, resulting in potential cost savings and benefits to future patients.
Methodical & Statistical Research
Oct 2023
This webinar will address when and why external control arms (ECA) are used, the acceptable types of data and methods to build ECAs, and circumstances under which ECAs are accepted from regulatory and HTA bodies.
Sponsored by Lane Clark & Peacock LLP
Oct 2023
In this webinar, we will give an overview of LLMs and share practical advice and cutting-edge examples about how to use them to help carry out real-world evidence (RWE) studies. We will also show how integrating GPT into population health analytics enables complex real-world datasets to be explored using simple language queries to transform the way that decision makers use data to identify unmet health needs.
Sponsored by Optum
Sep 2023
This webinar is aimed at those who perform or use the results of real-world evidence (RWE) studies. It aims to describe the use of predictive analytics and machine learning for causal inference in the context of the extremes for disease populations: rare diseases and common conditions such as obesity.
Jul 2023
In oncology, sequential use of treatments with different mechanisms of action is common practice to overcome cross-resistance . Over the past decade, treatment sequencing with novel immunotherapy and targeted agents has contributed to substantial improvement in clinical outcomes in cancer patients. However, such clinical practice introduces methodology challenges for HTA.
Health Policy & Regulatory
Oct 2023
The aim of this webinar is to discuss real-life examples on how biosimilar adoption has positively impacted care and patient access to biological therapies, focusing on testimonies from patient, policy, and healthcare professional representatives. Speakers are invited to converse on what the tangible benefits are that biosimilars have delivered for patients, and how biosimilar availability has supported access to care and the implementation of optimized disease management initiatives.
Sponsored by FIFARMA
Jul 2023
This webinar will inaugurate the third edition of the series of webinars sponsored by FIFARMA on Value and Access to Innovation, and will be focused on exploring the relationship between health and the economy and how to ensure the long term healthcare system sustainability.
Jun 2023
This webinar is aimed at all those who undertake research and development as well as value assessment of therapies and diagnostics in the rare disease space. It aims to expose the “diagnostic odyssey” and explain why a definitive diagnosis is not only important for patients but also for those assessing value. Objectives are to 1) explain what can be done to improve diagnosis in rare diseases and 2) why it matters in the context of value assessment.
Sponsored by Charles River Associates
Oct 2022
Biosimilars offer great potential for the patients, payers and the whole society. However, there exist policy barriers which can hinder this potential. The debate will analyze the challenges and opportunities for biosimilars uptake in Europe, Middle East and Canada.
Study Approaches
Sep 2023
This webinar will introduce several strategies for communicating the results of your study. These strategies can be used regardless of study methodology (eg, chart reviews, database analyses, economic models) and publication type (eg, abstract, poster, manuscript, report). As the field of HEOR continues to proliferate, the need for timely, clear, concise publications has never been greater.
Apr 2023
In this forum, the OSM Special Interest Group has selected leaders in the field of health economics to describe their approach to OSMs. Mohsen Sadatsafavi will introduce the Peer Models Network and PRISM service as part of "Open-access modelling as a companion to open-source modelling” illustrated with an example implemented for Chronic Obstructive Pulmonary Disease (the Evaluation Platform in COPD (EPIC) model.)
Oct 2020
In this webinar, we will be discussing this issue in relation to cancer immunotherapy. An overview of the survival extrapolation methods which could be used for cancer immunotherapies will be presented along with an assessment of their strengths and limitations. Finally, the presenters will provide attendees with some pointers to help with the selection of appropriate survival extrapolation models for these agents.
Jun 2020
This webinar will explore why and how to use qualitative research methods in conjunction with discrete choice experiments in healthcare. Speakers will discuss formative qualitative research for the identification and generation of attributes and levels and qualitative research for testing survey comprehension and decision-making processes.
Jun 2023
This webinar is aimed at all those who undertake research and development as well as value assessment of therapies and diagnostics in the rare disease space. It aims to expose the “diagnostic odyssey” and explain why a definitive diagnosis is not only important for patients but also for those assessing value. Objectives are to 1) explain what can be done to improve diagnosis in rare diseases and 2) why it matters in the context of value assessment.
Apr 2023
The webinar will provide an overview of past and current efforts in health equity, its role in health outcomes research, and its future implications in the field.
Sponsored by FIFARMA
Oct 2022
This webinar will focus on discussing how to ensure access for the right patient, to the right treatment, at the right time. We invited Max Newton, Engagement Manager at IQVIA as guest speaker. Max worked on the development of the FIFARMA "Patients Waiting to Access Innovative Therapies (WAIT) Indicator survey"; he also is leading a similar survey in Europe, the "EFPIA WAIT indicator".
Sponsored by FIFARMA
Aug 2022
This is the Second webinar of the Value and Access to Innovation webseries sponsored by FIFARMA. The series are structured around FIFARMA's VAI working group workstreams: (1) Funding: what is the relation between health & the economy and how to ensure the long term healthcare system sustainability, (2) Value: what are the value frameworks used by decision makers in LatAm and what is the impact on patient access, (3) Adoption: how to ensure access for the right patient, to the right treatment, at the right time.
Sponsored by GSK
Dec 2022
In this webinar, representatives from different stakeholder groups (patients, physicians, health economists and industry) will discuss the value of increasing the use of non-OS endpoints in reimbursement decision-making to their stakeholder groups. Using the example of multiple myeloma, the speakers will discuss how and when non-OS endpoints should be used, to support a future in which assessments of novel therapies are more fit-for-purpose.
Sep 2021
During this webinar, the speakers will present their respective studies on gene therapy in Duchenne muscular dystrophy, spinal muscular atrophy (SMA) and hemophilia. They will discuss the importance of the disease context, the qualitative research that influenced attribute selection, the selection of health preference method and design of the health preferences’ tasks, and how the study findings relate to the potential value of gene therapy.
Feb 2021
This webinar will present an insightful exchange on best practices, challenges and opportunities for market access of biosimilars in different regions worldwide.
Oct 2020
The webinar will present an overview of societal benefits of biosimilars, how these are measured, how the United States (US) and select markets are tracking in attaining these benefits, and potential solutions for advancing the evidence of potential benefits into action.
Sponsored by GSK
Dec 2022
In this webinar, representatives from different stakeholder groups (patients, physicians, health economists and industry) will discuss the value of increasing the use of non-OS endpoints in reimbursement decision-making to their stakeholder groups. Using the example of multiple myeloma, the speakers will discuss how and when non-OS endpoints should be used, to support a future in which assessments of novel therapies are more fit-for-purpose.
Sponsored by Biogen
Jun 2021
A one-hour educational webinar on the implications of matched adjusted indirect treatment comparisons in rare disease, using SMA as an example. Webinar will provide both statistical and clinical perspective.
Sponsored by Biogen
Feb 2021
This educational webinar will describe factors that affect the assessment of the clinical and economic value of medical innovations, highlight specific issues with relevance to the societal value of treatments for AD, and place these issues in the context of future health technology assessments for AD treatments.
Dec 2020
This educational webinar explores some of the key issues relating to long-term evidence needs within the context of HTA in AD and considers what can be done in the short, medium, and long term to address evidence needs.
Need More Information or Have Questions?
Contact us for more information on ISPOR education and training.